AIM: To study the effect of intravitreal injection of anti- vascular endothelial growth factor(VEGF)on best corrected visual acuity(BCVA)and multifocal-electroretinogram(mfERG)before and after treatment for choroidal neovascular disease.

METHODS: A total of 264 patients(332 eyes)with macular neovascularization(MCNV)and idiopathic choroidal neovascular disease(ICNV)who underwent pathologic myopia from January 2015 to January 2017 were enrolled in this study. Intraocular pressure and BCVA, fundus using 90D front mirror and slit lamp detection, and the fundus photograph, OCT, ICGA and FFA angiography, mfERG detection were taken. One month after the drug, 1mo after the final treatment, we recorded BCVA, intraocular pressure and mfERG and so on.

RESULTS: Ranibizumab was injected into the 254 eyes, and 78 eyes were injected with conbercept. There were 37 eyes injected once, 147 eyes were injected twice, 72 eyes were injected 3 times, 57 eyes were injected 4 times, 19 eyes 5 times. There were no significant differences on intraocular pressure between the two groups(P>0.05). The BCVA before treatment was significantly different compared with those 1mo after treatment and 1mo after the final treatment(P>0.05). The amplitude of Ring1, Ring2 and Ring4 increased after treatment, the difference was statistically significant.(P<0.05). The amplitude of Ring3 and Ring5 increased at 1mo after final treatment(P<0.05).

CONCLUSION:Intravitreal injection of anti-VEGF drugs has a significant effect on BCVA and mf ERG in patients with choroidal neovascular disease and is safe.